Integrated Cancer Repository for Cancer Research (iCaRe2)

study id #: NCT02012699

condition: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, CNS Tumor, CNS Cancer, Mesothelioma

status: Recruiting

The objectives of this project at UNMC and other IRB approved sites is to implement and maintain a comprehensive data and biospecimen bank known as the Integrated Cancer Repository for Cancer Research (iCaRe2). The data registry and biospecimen bank will provide core support services for future IRB approved multidisciplinary research on cancer and other chronic diseases carried out by members of the Fred and Pamela Buffett Cancer Center as well as internal and external research collaborators from different participating institutions/centers.

start date: November 2013

estimated completion: December 2099

last updated: November 5, 2018

phase of development: Not Available

size / enrollment: 9999

study design: Observational Model: Cohort
Time Perspective: Prospective

study description:
Currently, there are seven registries/tissue bank developed under the umbrella of iCaRe2: the Pancreatic Cancer Collaborative Registry (PCCR), Thyroid Cancer and Tumor Collaborative Registry (TCCR), GenitoUrinary Cancer Collaborative Registry (GUCaRe), Thoracic Oncology Collaborative Registry (TOCR), Gastrointestinal and Abdominal Cancer Collaborative Registry (GACCaRe), Head and Neck Cancer Collaborative Registry (HNCCR), Central Nervous System Tumor Collaborative Registry (CTCR) for collaborative multi-center research. These Cancer Registries (CR) were established to unite participating centers with expertise in cancer epidemiology, genetics, biology, early detection and patient care to facilitate the rapid and uniform collection of critical information and biological samples to be used in developing prevention, detection and treatment strategies against cancer. Fred and Pamela Buffett Cancer Center also adopted the caTISSUE Suite (https://cabig.nci.nih.gov/tools/catissuesuite), a biorepository tool that has been developed under the NCI's cancer Biomedical Informatics Grid (caBIG®) umbrella. The Cancer Registry (CR) database is coupled with the biospecimen annotation database (caTISSUE) to manage activities associated with the biospecimen inventorying, tracking, and basic annotation. It provides quality assurance for all these activities and permits the users to track the collection, storage and distribution (derivation and aliquot) of specimens. This consolidated tissue bank will continue to collect and store comprehensive data on cancer patients, survivors and high-risk individuals. The tissue bank couples with the caTissue Suite for annotation and management of the biospecimen data to be collected. Consolidating all the registries into one tissue bank will foster and improve the efficiency of cancer-related research and facilitates collaborations among centers. The PI from each registry will remain the sole contact and will maintain responsibility of the conduct of each registry. For the purpose of consolidation into one IRB application, each PI is being assigned as Sub-PI. Namely, PCCR - Dr.Aaron Sasson, TCCR - Dr. Whitney Goldner, GUCaRe - Dr. Chad LaGrange , TOCR - Dr.Karin Trujillo, GACCaRe- Dr. Jason Foster, HNCCR- Dr. Russell Smith, CTCR- Dr. Nicole Shonka respectively.

primary outcomes:

• Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC) [ Time Frame: 25 years ] [ Designated as safety issue: No ]
  This is a registry that will continue to accrue patients indefinitely

secondary outcomes:

• Procurement and banking of excess biological material for future analysis [ Time Frame: 25 years ] [ Designated as safety issue: No ]
  This is a registry and biobank and will continue to accrue indefinitely

inclusion criteria:
1. All adults (male and female, age 19 and older) who have diagnosis of cancer.
2. All adults considered to be an "at risk individual for cancer", such as but not limited to a tumor, mass, nodules, family history of cancer, or suspicious clinical findings.
3. Able to provide informed consent.
4. English speaking.

exclusion criteria:
1. Individual younger than 19 years of age. 2. Individual who is unable to provide informed consent.

sponsor: University of Nebraska

contacts:
Whitney Goldner, MD
402-559-3579
wgoldner@unmc.edu
Alice Kueh, MS
402-559-8511
akueh@unmc.edu

investigators: Whitney Goldner, MD

locations: United States